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non-coverage decision. Of the positive decisions, 22 were associated with an economic 
evaluation that estimated the medical intervention to be dominant (costs less and more
effective than the alternative), 8 with an incremental cost-effectiveness ratio (ICER)
of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, 
and 8 with an ICER greater than $100,000 (2008 USD). In four of the positive cover-
age decisions the intervention was dominated (costs more and was less effective than 
the alternative). Of the non-coverage decisions, 3 interventions were estimated to be
dominant, 6 were associated with an ICER less than $30,000, one with an ICER of 
approximately $200,000, and four were dominated. Fourteen decision memos cited 
or discussed cost-effectiveness information. CONCLUSIONS: CMS is covering a
number of interventions that do not appear to be cost-effective by traditional stan-
dards. While we identiﬁ ed several instances where cost-effectiveness evidence was cited 
in NCDs, we found no clear evidence of an implicit constant ﬁ xed cost-effectiveness 
threshold.
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OBJECTIVES: To examine the out of pocket spending on psychotropic medications 
by elderly Medicare beneﬁ ciaries before and after the implementation of Medicare
Part D. METHODS: The effect of Part D was measured using 2005–2006 pharmacy
claims data from one of the largest retail pharmacy chains in the United States. The 
psychotropic medications examined in this study included antidepressants, antipsy-
chotics benzodiazepines and barbiturates. In addition to evaluating overall out of 
pocket burden in 2005 and 2006, the study examined out of pocket burden among 
Medicare-Medicaid dual eligible beneﬁ ciaries, non-dual Part D enrollees, and those
who did not enroll in Medicare Part D. The out of pocket burden was calculated as
a percentage of total pharmacy reimbursement involving elderly persons 65 years or 
older. RESULTS: The proportion of out of pocket expenditures in total pharmacy 
reimbursement dropped 7.62% (from 40.43% to 32.81%) for antidepressants, 6.24% 
for antipsychotics (from 27.82% to 21.58%), but increased 12.15% for benzodiaze-
pines (from 62.64% to 74.79%), and 9% (from 71.96% to 80.56%) for barbiturates.
Dual eligible beneﬁ ciaries were the group most severely affected by the policy change. 
For dual eligible beneﬁ ciaries who were on any of the four drug categories, their yearly
out of pocket expense increased extensively. The most dramatic change was observed 
in dual eligibles using benzodiazepines. Their out of pocket expenditure increased by
around 12 folds from 2005 to 2006. Non-dual Part D enrollees beneﬁ ted the most
from the new drug policy. The most signiﬁ cant cost saving was found in non-dual Part 
D enrollees who were on antidepressants (from 62.23% to 32.97%) and antipsychot-
ics (from 55.24% to 38.30%). CONCLUSIONS: The implementation of Part D was 
associated with reduced out of pocket psychotropic prescription burden on non-dual
Part D enrollees, however, out-of –pocket burden on the dual eligible beneﬁ ciaries
severely increased.
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OBJECTIVES: We compared patient preference and satisfaction between two osteo-
porosis medications: alendronate (ALN 70 mg tablets) taken orally once weekly (QW)
and denosumab (DMAb 60 mg; investigational agent) injected subcutaneously (SC) 
every 6 months (Q6M). METHODS: Preference and satisfaction were evaluated as
part of a phase 3, double-blind, double-dummy study to determine the effects of tran-
sitioning subjects from ALN to DMAb. Postmenopausal women q55 with a lumbar 
spine or total hip T-score a2.0 and q4.0 who were receiving ALN therapy for q6 
months were eligible. After a 1-month ALN run-in phase, subjects were randomized
to treatment with continued ALN QW  placebo injection SC Q6M or DMAb SC
Q6M  QW placebo tablet. At study conclusion, subjects completed a 34-item ques-
tionnaire. Pre-determined endpoints of preference and satisfaction were measured by 
asking subjects to choose the tablet, the injection, or neither, in response to questions 
on preference (“Which do you prefer?”) and satisfaction (“With which frequency of 
administration have you been more satisﬁ ed?”). RESULTS: The subjects (n  251 ALN,
n  253 DMAb) had a mean age of 67.6 years and a median length of prior bisphos-
phonate use of 36 months (range 6 to 192). 483 (95.8%) women took the questionnaire
(240-ALN, 243-DMAb). Of the subjects who responded to the question on preference 
(240-ALN, 240-DMAb) or satisfaction (237-ALN, 242-DMAb), signiﬁ cantly more 
subjects preferred a 6-month injection vs. a weekly oral tablet (ALN:66%-Q6M injec-
tion, 19%-QW tablet, 15%-neither, p  0.0001; DMAb:70%-Q6M injection, 19%-
QW tablet, 12%-neither, p  0.0001) and signiﬁ cantly more subjects reported greater 
satisfaction with the frequency of 6-month vs. weekly dosing (ALN:68%-Q6M injec-
tion, 19%-QW tablet, 14%-neither, p  0.0001; DMAb:70%-Q6M injection, 16%-
QW tablet, 14%-neither, p  0.0001). CONCLUSIONS: A preference for and a greater 
satisfaction with a 6-month injection vs a weekly oral tablet was demonstrated in sub-
jects previously receiving and tolerating ALN therapy.
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OBJECTIVES: RA clinical studies using the SF-36 Physical Function (PF) scale and 
Health Assessment Questionnaire (HAQ) have identiﬁ ed limitations in each instru-
ment’s sensitivity across the full range of disease severity. Item Response Theory (IRT) 
estimates were used to develop a composite of both instruments (PF–HAQ) to provide
a more sensitive measure of physical health. METHODS: Data for 799 patients from
a 2-year randomized control study of adalimumab in early RA (3 years) were 
employed. Patients received adalimumab plus methotrexate; adalimumab monother-
apy; or methotrexate monotherapy. Composite PF–HAQ scores were compared indi-
vidually with PF and HAQ using 1) comparison of ﬂ oor and ceiling effects; 2) 
ANCOVA models with ACR criteria classiﬁ cation or treatment as factors (covariates: 
sex, age, BMI); and 3) receiver operating characteristics (ROC) analyses using ACR50
criteria as a gold standard. RESULTS: At baseline, 6.2% of patients were at ﬂ oor for
the PF. At endpoint, 37.7% and 14.2% of HAQ and PF scores, respectively, were at
ceiling. IRT scores, by deﬁ nition, have no ceiling or ﬂ oor. Signiﬁ cant differences across
treatment groups were obtained (F [2526]  12.21, 7.48, 3.02, p  0.001 for all com-
parisons). PF–HAQ had signiﬁ cantly more power than either individual scale to detect 
treatment differences (F-statistic ratios of PF–HAQ with PF and HAQ were 1.6 and 
4.0, respectively). PF–HAQ was better than PF at detecting differences in endpoint
ACR criteria (F-statistic ratio for PF–HAQ to PF was 1.28). ROC analyses indicated 
that PF–HAQ provided better measurement precision (p  0.001) vs. PF and equiva-
lent/better precision vs. HAQ (p  0.14) (AUC: PF 0.80, 95% CI: 0.79–0.81; HAQ: 
0.83 [0.82–0.85]; PF–HAQ: 0.84 [0.83–0.85]). CONCLUSIONS: Combining PF and 
HAQ measures into a single measure eliminated ﬂ oor/ceiling effects, and provided 
greater efﬁ ciency in discriminating treatment effects, as well as greater sensitivity vs. 
common diagnostic criteria.
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OBJECTIVES: To assess the impact of compliance with biologic therapies on clinical
measures, including symptoms, quality of life (QOL), and medical resource use in 
rheumatoid arthritis (RA) patients. METHODS: Patient-reported data were collected
from the 2008 Rheumatoid Arthritis Patient Study, an Internet survey of RA patients. 
Clinical measures and medical resource use (number of surgeries, emergency room 
and physician visits, and hospitalizations within six months) were compared among 
three groups: patients who used biologics before but discontinued; patients who cur-
rently use biologics but skipped doses within the last 12 months; and patients who 
currently use biologics without skipping. Symptoms included morning stiffness, 
fatigue, and pain scores measured on a Likert scare from zero (no symptoms) to 10 
(severe symptoms). QOL was measured by the mental component summary (MCS) 
and physical component summary (PCS) of the Health Survey Short Form (SF-36).
RESULTS: Of 2,048 respondents, 475 (23.2%) used biologic therapies, 74.3% were
female, and the average age was 51.9 years. The average duration of RA was 11.9
years, with 20.0% reporting severe disease. Among patients who used biologics, 148
(31.2%) patients discontinued and 80 (16.8%) patients reported skipping doses in the
last 12 months. Compared to the groups who discontinued, or skipped biologic doses, 
the current users who did not skip had the best symptom and QOL scores: morning 
stiffness (6.51, 5.91, 5.77), fatigue (7.00, 6.96, 6.23), pain (6.51, 6.18, 5.71), MCS
(38.0, 41.7, 41.9), and PCS (30.4, 29.2, 32.8) (all P  0.05). There were no statistical 
differences in medical resource use except physician visits, which were signiﬁ cantly 
lower in current users who did not skip doses. CONCLUSIONS: Patients who were 
compliant with their biologic therapy had better outcomes compared with patients
who discontinued or skipped doses. Compliance with biologic therapy is an important
factor optimizing effective treatment of RA.
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OBJECTIVES: Methods have been well-established to estimate the excess amount of 
health care services and work loss costs of RA and, to a lesser extent, caregiver costs. 
To estimate the comprehensive societal cost of RA, we assessed intangible costs associ-
ated with functional disability/quality of life and mortality legal system jury award
